LAUR Repository

Show simple item record

dc.contributor.author Kisgen, Jamie J.
dc.contributor.author Mansour, Hanine
dc.contributor.author Unger, Nathan R.
dc.contributor.author Childs, Lindsay M,
dc.date.accessioned 2016-09-29T12:06:47Z
dc.date.available 2016-09-29T12:06:47Z
dc.date.copyright 2014 en_US
dc.date.issued 2016-09-29
dc.identifier.issn 1695-0674 en_US
dc.identifier.uri http://hdl.handle.net/10725/4455
dc.description.abstract Purpose. The mechanism of action, pharmacokinetics, pharmacodynamics, and clinical efficacy and safety of an investigational second-generation oxazolidinone are reviewed. Summary. Tedizolid is a protein synthesis inhibitor in clinical development for the treatment of gram-positive infections. Similar to linezolid, tedizolid works by binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the 70S initiation complex and inhibiting protein synthesis. Tedizolid has demonstrated potent in vitro activity against multidrug-resistant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, and vancomycin-resistant enterococci (VRE), including some linezolid-resistant strains. Tedizolid has a favorable pharmacokinetic profile that allows for once-daily dosing and easy i.v.-to-oral conversion. Unlike linezolid, tedizolid has not been shown to interact with serotonergic agents in clinical studies. Two Phase III studies in patients with acute bacterial skin and skin structure infections have demonstrated the noninferiority of 6 days of tedizolid therapy (200 mg i.v. or orally once daily) relative to 10 days of linezolid therapy. In clinical trials to date, overall rates of treatment-related adverse effects with linezolid and tedizolid were comparable (40.8% versus 43.3%), with nausea being the most commonly reported adverse effect associated with tedizolid use (16% of patients). Planned studies will investigate tedizolid's potential role in the treatment of community-acquired bacterial pneumonia, hospital-acquired/ ventilator-associated bacterial pneumonia, and bacteremia. Conclusion. Tedizolid is an investigational oxazolidinone antibiotic for the treatment of multidrug-resistant gram-positive pathogens such as MRSA, Streptococcus pneumoniae, and VRE, including some linezolid-resistant strains. en_US
dc.language.iso en en_US
dc.title Tedizolid en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle A new oxazolidinone antimicrobial en_US
dc.author.school SOP en_US
dc.author.idnumber 201205628 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal American Journal of Health-System Pharmacy en_US
dc.journal.volume 71 en_US
dc.journal.issue 8 en_US
dc.article.pages 621-633 en_US
dc.identifier.doi http://dx.doi.org/10.2146/ajhp130482 en_US
dc.identifier.ctation Kisgen, J. J., Mansour, H., Unger, N. R., & CHILDS, L. M. (2014). Tedizolid: a new oxazolidinone antimicrobial. American Journal of Health-System Pharmacy, 71(8), 621-633. en_US
dc.author.email hanine.mansour@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://academic.oup.com/ajhp/article/71/8/621/5111253?login=true en_US
dc.orcid.id https://orcid.org/0000-0001-6383-0288

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account